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Objective. Determine the impact of Orlistat-induced weight loss on metabolic proﬁle and cardiovascular function in severely
obese patients with type 2 diabetes. Methods. Twenty-nine patients were randomized either to a nonplacebo control group or
to a treatment group with Orlistat thrice a day. Metabolic proﬁle, anthropometric parameters, heart rate variability indices, and
echocardiographic variables were measured before and after a 12-week treatment period. Results. Treatment with Orlistat induced
a modest but signiﬁcant weight loss compared to controls (3.7 ± 3.0v e r s u s0 .5 ± 2.2kg,resp.;P = .003). There was signiﬁcant
decrease in fasting glycemia (7.9±3.0v e r s u s6 .7±2.2mmol/L;P = .03) and signiﬁcantimprovements in left ventricular diastolic
function (P = .03) and in the sympathovagal balance (LF/HF ratio) (P = .04) in the Orlistat group. Conclusion. These results
suggest that a modest weight loss improves fasting glycemia, left ventricular diastolic function, and sympathovagal balance in
severely obese patients with type 2 diabetes.
1.Introduction
Severe obesity is deﬁned as a body mass index (BMI)
>40kg/m2 which is associated with comorbidities such as
insulin resistance, diabetes mellitus, systemic hypertension,
dyslipidemia, and cancer. Obesity is an independent risk
factor for increased cardiovascular morbidity and mortality
[1]. Furthermore, severely obese subjects have an increased
total mortality with a concomitant increased risk of sudden
death, which may be caused by fatal arrhythmias [1].
Heart rate variability (HRV) which is the ﬂuctuation
of heart rate around mean heart rate that may be assessed
with a 24-hour cardiac Holter monitoring provides valuable
information on the activity of the cardiac autonomic ner-
vous system (ANS). The ANS is an important contributor
to the regulation of both the cardiovascular system and
energy expenditure and it is assumed to play a role in
the pathophysiology of obesity and related complications
[1, 2]. In obese subjects, many studies have observed
abnormalities in the sympathetic and the parasympathetic
ANSactivity, which couldpartlyexplain therelation between
obesity,comorbidities,suddendeath,andarrhythmias [1,3].
Available data regarding the metabolic and ANS impacts of
weight loss in severely obese subjects by other methods than
gastric bypass [4, 5] and hypocaloric diet [3, 6–9] are sparse.
Excess body fat also directly inﬂuences heart function
[1]. Obesity is associated with decreased left ventricular
(LV) systolic function and impaired LV diastolic function
[1, 10]. Whereas some studies using surgical procedures
have reported that substantial weight loss induces signiﬁcant
improvements in LV diastolic function [10–14], the eﬀect of
modest weight loss on LV diastolic dysfunction in obese sub-
jects has beenless extensively investigated buthas neverbeen
reported in severe obesity. Diet and exercise programs are
associated with disappointing long-term results on weight
loss in severely obese subjects [15]. Weight loss medication
is recommended for subjects with a BMI >30kg/m2 or
with a BMI >27kg/m2 associated with ≥1r i s kf a c t o ro f
cardiovascular disease [16]. Orlistat is a gastrointestinal
lipase inhibitor, reducing fat absorption, which may result in
weight loss of approximately 5%–10% of the initial weight
after one year [17]. It may be relevant to investigate the2 Journal of Obesity
impact of modest weight loss on LV diastolic function and
on HRV since these parameters may be associated with
increased cardiovascular risk [18, 19]. This pilot study aimed
todeterminetheimpactofweightlossinducedbyOrlistaton
HRV and on LV diastolic function in severely obese patients
with type 2 diabetes.
2.Methods
2.1. Subjects. A total of 38 severely obese patients with type
2 diabetes were recruited from the waiting list of bariatric
surgery in our Institution. The experimental protocol was
approved by the ethics committee of IUCPQ and we
certify that all applicable institutional and governmental
regulations concerning the ethical use of human volunteers
were followed during this research. All the subjects gave
their written informed consent. Subjects 18 years or older
and treated with antidiabetic medication and/orinsulin were
included. Subjects were excluded if they used medication
known to inﬂuence HRV or if they had documented chronic
heartfailureand/orkidneyfailure.Subjectswererandomized
to a control group or to a treatment group, which consisted
of120mg ofOrlistat (Xenical Roche,Nutley,NJ, USA)thrice
a day, 30 minutes before meal, for 12 weeks. The medication
wasprovidedatno cost.Forboth treatedand controlgroups,
no reinforced speciﬁc nutritional intervention was recom-
mended during this study other than the usual nutritional
advice regarding the medication, reﬂecting a real clinical
context. Follow-up was systematically conducted by phone
for all subjects at 4 and 8 weeks into the study, in order
to ensure subject’s compliance with the medication and to
noteanysigniﬁcant changesin lifestyle.Ninesubjectsdidnot
complete the study. In the control group, (1) one underwent
bariatric surgery, (2) one had medication change within
follow-up period, and (3) ﬁve did not attend their follow-up
visit. In the treated group, (1) one had clinically signiﬁcant
side eﬀectson the medication, and (2) onedid not attend the
follow-up visit.
2.2. Anthropometric Measurements. Total body mass, lean
and fat mass, height, and BMI have been determined
with an electrical bioimpedance balance (Tanita TBF-350,
Tokyo, Japan). Waist circumference was measured using
standardized method with an inelastic tape. Blood pressure
and resting heart rate were measured following a 30-minute
resting period while subjects were lying on their side during
the echocardiogram study. Blood pressure was measured
using an adapted size blood pressure cuﬀ and an electronic
sphygmomanometer (Welch-Allyn, 5200 series, Arden, NC,
USA).
2.3. Biochemistry. Blood sample was taken after a 12-hour
fast. Glycemia was determined using an enzymatic method
(Hitachi, 717 Auto analyzer; Roche, Laval, Canada) and
glycated hemoglobin (HbA1c) was measured by binding
aﬃnity (Abbot IMX, Mississauga, Canada). Plasma choles-
terol and triglycerides concentrations were measured using
previously described methods (Hitachi, 717 Auto analyzer;
Roche, Laval, Canada) [20, 21]. Serum HDL-cholesterol
was analysed with an enzymatic precipitation of LDL-
cholesterol and VLDL-cholesterol, using phosphotungstate
and MgCl2. LDL-cholesterol concentration was calculated
with Friedewald’s formula [22].
2.4. Echocardiography. Echocardiographic measures were
performed with a commercial ultrasound system (Sonos
5500; Hewlet Packard, Andover, Massachusetts). Standard
parasternal, short-axis, and apical views were performed
in accordance with the recommendations of the American
Society of Echocardiography and the same observer, who
was blinded to randomisation, obtained all recordings
and measurements. Left ventricular diastolic dysfunction
(LVDD), using transmitral and pulmonary veins recordings,
was evaluated using well-standardized criteria as previously
reported [20, 21]. Tissue Doppler was not performed.
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LVEDD represents the left ventricle end diastolic dimension,
IVST the interventricular septal thickness, and PWT the
posterior wall thickness.
2.5. Heart Rate Variability. Heart rate variability (HRV)
was derived from a 24-hour Holter monitoring system
(Marquette Electronics Inc., Milwaukee, WI) in all subjects
during normal daily life activity [21]. Numerous indices
in the frequency and the time domains were determined
[7, 21]: mean value of all RR intervals (mean NN), standard
deviation of the RR intervals (SDNN), standard deviation of
the mean NN intervals for each 5 minutes period (SDANN),
square root of the mean squared diﬀerence of successive
RR intervals (rMSSD), percentage of diﬀerences between
adjacent normal RR intervals exceeding 50milliseconds
(pNN50), high frequency (HF), and low frequency (LF).
Within the 24-hour evaluation, three periods were assessed:
(1) 24 hours, (2) daytime period deﬁned as 8:00 AM to
8:00 PM, and (3) night time period deﬁned as 12:00 AM to
6:00 AM. The separation into daytime and night time was
arbitrary [7].
2.6. Statistical Analysis. Data are presented as mean ±
standard deviation unless otherwise speciﬁed. Comparisons
between normal, spontaneous, and pseudonormal pattern
of LV ﬁlling pre and posttreatment were conducted with
a mixed ANOVA design. This analysis allowed us to ﬁrst
compare groups (treatment versus control) in regards to
baseline data and to determine the treatment eﬀect as well as
interactions between groups and treatment. The factor with
randomeﬀectwaslinkedto subjects. The dependentvariable
associated to LV diastolic function was analysed using a
cumulative multinomial distribution with an independent
covariance structure. Thereafter, if signiﬁcant diﬀerences
occurred, a posteriori Tukey’s comparison technique was
performed to determine diﬀerences. Relationships among
variables were measured using Pearson’s correlation coeﬃ-
cients. In order to test the normality distribution of the data,Journal of Obesity 3
Table 1: Baseline characteristics of type 2 diabetic severely obese subjects before and after treatment.
Control group Treatment group
Pre Post Pre Post
N 13 13 16 16
Age (years) 48 ± 11 — 47 ± 9—
Duration of diabetes (years)1,3 4.8 ± 4.6 — 7.2 ± 6.1 —
Men/Women (number) 7/6 7/6 7/9 7/9
Weight (kg) 142.6 ± 34.6 142.1 ± 35.0 129.6 ± 17.4 125.9 ± 17.5∗‡
BMI (kg/m2) 51.2 ± 9.2 51.2 ± 9.0 45.9 ± 7.3 44.8 ± 7.5∗‡
Waist circumference (cm) 145.8 ± 20.8 144.3 ± 20.6 138.4 ± 14.7 133.9 ± 17.0∗
Fat percentage (%)2 48.5 ± 5.4 48.8 ± 4.1 45.7 ± 8.3 45.6 ± 8.7
Fat mass (kg)2 67.3 ± 13.6 66.2 ± 13.8 59.1 ± 13.1 57.4 ± 13.5
Fat free mass (kg)2 72.3 ± 18.9 70.0 ± 17.8 70.4 ± 15.4 68.5 ± 15.2∗
Resting HR (beat/min) 83 ± 78 4 ± 12 80 ± 12 78 ± 11
SBP (mmHg) 127 ± 20 126 ± 15 137 ± 18 127 ± 13
DBP (mmHg) 71 ± 10 70 ± 97 4 ± 12 70 ± 11
Fasting glycemia (mmol/L)1,3 8.0 ± 2.5 8.1 ± 2.5 7.9 ± 3.0 6.7 ± 2.2∗
HbA1c (%)1 7.3 ± 1.1 6.7 ± 0.9∗ 7.3 ± 2.1 6.6 ± 1.3∗
Total cholesterol4 4.8 ± 0.8 4.7 ± 0.7 4.5 ± 0.7 4.3 ± 0.8
HDL-cholesterol (mmol/L)4 1.3 ± 0.2 1.2 ± 0.3 1.2 ± 0.3 1.2 ± 0.3
LDL-cholesterol (mmol/L)4 2.7 ± 0.8 2.5 ± 0.7∗ 2.5 ± 0.6 2.2 ± 0.8∗
Triglyceride (mmol/L)4 1.8 ± 0.5 2.0 ± 0.7 1.7 ± 0.6 1.9 ± 0.8
Mean ± standard deviation; ∗P<. 05: pre versus post; ‡P<. 05: control versus treatment; BMI: Body mass index; DBP: Diastolic blood pressure; HR:
Heart rate; MBP: Mean blood pressure; SBP: Systolicblood pressure.
1One subject missing in the control group.
2Two subjects missing in the control group.
3One subject missing in the treatment group.
4Two subjects missing in the treatment group.
the Shapiro-Wilk test was performed. Brown and Forsythe’s
variation of Levene’s statistics test was used to verify the
homogeneity of variances. A P value inferior to .05 was
considered statistically signiﬁcant. Data were analysed using
the statistical packages Sigma Stat (Chicago, IL, USA) and
SAS (SAS Institute Inc., Cary, NC, USA).
3.Results
3.1. Clinical Parameters. Table 1 presents clinical character-
istics of patients in both groups before and after treatment.
There were no signiﬁcant statistical diﬀerences between the
two groups for all parameters at the beginning of the study
(Table 1). After 3 months of treatment with Orlistat, there
was a signiﬁcant reduction in body weight (P<. 001), BMI
(P = .003), and waist circumference (P = .005). When
compared to the control group, mean weight loss (3.7 ± 3.0
versus 0.5 ± 2.2kg; P = .003), corresponding to a percentage
of weight loss of 2.9 ± 2.5 versus 0.3 ± 1.5% (P = .003),
was statistically diﬀerent. Weight loss in the treatment group
was associated with improvements infasting glycemia,which
d e c r e a s e do n l yi nt h eg r o u pt r e a t e dw i t hO r l i s t a t( P = .03).
However,there was a signiﬁcant decrease in HbA1c (controls:
P<. 001 and treated: P = .02) as well as in the LDL-
cholesterol levels in both groups (controls: P = .05 and
treated: P = .03). In the treatment group, fat-free mass
decreased signiﬁcantly (P = .03). No signiﬁcant diﬀerence
was observed between the two groups after treatment for the
other anthropometric and metabolic parameters (Table 1).
3.2. Heart Rate Variability
3.2.1. Time Domain. In the 24-hour HRV indices, there was
a signiﬁcant increase in rMSSD (P = .02) as well as in
pNN50 (P = .03) in the treated group following weight loss
(Table 2). While there was no signiﬁcant change in the HRV
daytime indices, night time measures showed a signiﬁcant
improvementinrMSSDinthetreatedgrouponly(P = .023).
3.2.2. Spectral domain. Following weight loss, high-
frequency (HF) power measured during the 24-hour period
increased signiﬁcantly (P = .05), but during daytime and
night time, increments did not reach statistical signiﬁcance
(daytime: P = .056 and night time: P = .1) (Table 2). The
LF/HF ratio decreased signiﬁcantly in the treated group in
the 24-hour assessment (P = .038) as well as during daytime
(P = .006).
3.3. Echocardiography. Echocardiographic parameters mea-
sured in both groups as well as normal values are shown
in Table 3. There were no statistically signiﬁcant diﬀerences
in heart dimensions or parameters of LV diastolic function
between the control group and the Orlistat-treated group at4 Journal of Obesity
Table 2: Heart rate variability indices in severely obese subjects with type 2 diabetes before and after treatment.
(a) 24 hour
Control group Treatment group
Pre Post Pre Post
N 13 12 16 16
Mean NN (ms) 768 ± 86 786 ± 111 775 ± 102 796 ± 101
SDNN (ms) 106 ± 34 106 ± 30 102 ± 25 112 ± 23
SDANN (ms) 93 ± 38 91 ± 35 88 ± 22 97 ± 22
rMSSD (ms) 26 ± 15 28 ± 16 24 ± 10 30 ± 10∗
pNN50 (%) 7 ± 10 8 ± 10 6 ± 79 ± 8∗
HF (ln) 4.4 ± 1.0 4.6 ± 0.9 4.5 ± 0.9 4.9 ± 0.7∗
LF (ln) 5.6 ± 0.9 5.7 ± 0.7 5.7 ± 1.0 5.9 ± 0.7
LF/HF ratio 3.7 ± 1.9 3.4 ± 1.7 3.3 ± 1.1 2.8 ± 1.3∗
(b) Daytime
Control group Treatment group
Pre Post Pre Post
N 13 12 16 16
Mean NN (ms) 733 ± 100 762 ± 133 734 ± 104 742 ± 105
SDNN (ms) 80 ± 29 85 ± 30 80 ± 22 84 ± 22
SDANN (ms) 68 ± 23 69 ± 26 63 ± 18 66 ± 21
rMSSD (ms) 21 ± 18 26 ± 20 21 ± 82 5 ± 9
pNN50 (%) 5 ± 13 7 ± 13 4 ± 56 ± 7
HF (ln) 3.8 ± 1.2 4.3 ± 1.2 4.1 ± 1.0 4.6 ± 0.8
LF (ln) 4.9 ± 0.9 5.4 ± 0.8 5.5 ± 1.0 5.7 ± 0.7
LF/HF ratio 3.8 ± 2.4 3.7 ± 2.5 4.0 ± 1.8 3.2 ± 1.2∗
(c) Night time
Control group Treatment group
Pre Post Pre Post
N 13 12 16 16
Mean NN (ms) 840 ± 86 827 ± 96 851 ± 112 890 ± 105
SDNN (ms) 88 ± 45 86 ± 30 83 ± 25 85 ± 23
SDANN (ms) 57 ± 39 60 ± 31 57 ± 18 53 ± 16
rMSSD (ms) 32 ± 17 30 ± 11 31 ± 15 36 ± 16∗
pNN50 (%) 10 ± 12 10 ± 10 11 ± 12 15 ± 14
HF (ln) 5.1 ± 1.1 4.9 ± 0.9 5.0 ± 1.0 5.4 ± 1.0
LF (ln) 6.2 ± 1.1 5.9 ± 0.9 6.0 ± 1.0 6.2 ± 0.9‡
LF/HF ratio 3.7 ± 2.6 3.2 ± 2.0 2.9 ± 1.4 2.6 ± 1.7
Mean ± standard deviation; ∗P<. 05: pre versus post; ‡P<. 05: control versus treatment; ln: logarithmic transformation; HF: High frequency; LF: Low
frequency; Mean NN: Mean value of all RR intervals; pNN50: Percentage of intervals diﬀering of ≥50ms than the preceding interval; rMSSD: square root of
the mean squared diﬀerence of successive RR intervals; SDANN: Standard deviation of the mean NN intervals for each 5 minutes period; SDNN: Standard
deviation of the RR intervals.
the beginning of the study. Despite normal baseline values,
we observed a nonstatistical increment in ejection fraction
after treatment with Orlistat (P = .054), the values after
treatment being also signiﬁcantly greater than the ejection
fraction values of the control group (P = .04). There were
11 out of 16 subjects with impaired LV diastolic function (7
spontaneous and 4 pseudonormal LVDD) in the treatment
group while there were 7 out of 13 subjects (5 spontaneous
and 2 pseudonormal LVDD) in the control group (Figure 1).
Isovolumetric relaxation time, A wave velocity, E/A ratio,
deceleration time, as well as the A wave duration were
not statistically diﬀerent following treatment. However, E
wave velocity signiﬁcantly increased in the treatment group
(P = .046). During the Valsalva manoeuvre, we observed a
signiﬁcant decrease of the A wave velocity in the treatment
group (P = .007), concomitant to a signiﬁcant increase in
the E/A ratio (P = .024). This increment was statistically
diﬀerent to the eﬀect observed in the control group (P =
.027). Accordingly, for the patients with a pseudonormal
diastolic function, using the E/A value assessed during theJournal of Obesity 5
Table 3: Echocardiographic parameters in severely obese subjects with type 2 diabetes before and after treatment.
Normal values Control group Treatment group
Pre Post Pre Post
N 13 13 16 16
Aortic root (mm) 20–37 33 ± 43 5 ± 4∗ 33 ± 43 3 ± 4‡
IVS (mm) 6–11 11 ± 11 11 ± 11 11 ± 21 11 ± 2
PW (mm) 6–11 10 ± 21 10 ± 11 11 ± 11 10 ± 1∗
LA (mm) 19–40 42 ± 44 1 ± 54 2 ± 44 1 ± 3
RV diastolic (mm) 7–23 26 ± 42 6 ± 42 6 ± 32 6 ± 3
LV diastolic (mm) 35–57 53 ± 85 4 ± 95 0 ± 45 1 ± 3
LV systolic (mm) 20–39 34 ± 92 35 ± 101 29 ± 41 30 ± 4
LV mass (g/m)4 M < 163 226 ± 742 233 ± 612 209 ± 533 198 ± 462∗
W < 121
Ejection fraction (%) >50 60 ± 11 60 ± 13 64 ± 56 7 ± 4
Mean ± standard deviation; ∗P<. 05: pre versus post; ‡P<. 05: control versus treatment; IVS: Interventricular septum; LA: Left atrium; LV: Left ventricle;




4Normal values: <163g/m for men and <121g/m for women [24].
Valsalva manoeuvre in order to account for the increased
pressure of LV ﬁlling, there was a signiﬁcantly enhanced
LV diastolic function in the treatment group (P = .014).
There was no diﬀerence in the other indices of LV diastolic
function.
Figure 1showstheinﬂuenceofweightlostonLVdiastolic
function. Thirty-height percent of the subjects (6/16) in the
treatment group signiﬁcantly improved their LV diastolic
function (P = .03). In contrast, in the control group, there
was no improvement (P = .35)exceptforonesubjectwhile 3
subjectsworsentheirLVdiastolicfunction.The amelioration
ofLVdiastolic function in thetreated group was signiﬁcantly
diﬀerent to the control group (P = .026).
3.3.1. Correlations. As expected, a positive correlation was
found between body weight and BMI and LV mass (r =
0.68 and r = 0.44, resp.; both P<. 001). An inverse
correlation was also observed between body weight, BMI,
and LV ejection fraction (r =− 0.48 and r =− 0.52, resp.;
both P<. 001). There was positive correlation between E/A
ratio and 24-hour measurement of HF (r = 0.361; P<. 01),
rMSSD (r = 0.456; P<. 001), and pNN50 (r = 0.458;
P<. 001).Changesin E/Aratio and deltaLF/HFratio during
24-hour and daytime also showed correlations (r = 0.377;
P = .048 and r = 0.458; P = .014, resp.).
4.Discussion
We observed that modest Orlistat-induced weight loss
enhances sympathovagal balance and cardiac function in
severely obese patients with type 2 diabetes. After a 3-month
treatment period with Orlistat, subjects lost signiﬁcantly
more weight than subjects in the control group.
Akehi et al. reported that very-low calorie diet-induced
weight loss in moderately obese subjects improved NN,
SDNN, SDANN, rMSSD, HF, and LF/HF ratio values [6].
This was interpreted as an improvement in the sympatho-
vagal balance. Similarly, Poirier et al. [7]r e p o r t e dt h a ta
10%diet-inducedweightloss in8severelyobesesubjectswas
associated with signiﬁcant improvement in autonomic car-
diac modulation through enhancement of parasympathetic
modulation which translates clinically into decreased heart
rate and increased HRV. In our study, rMSSD, pNN50, and
HFvaluesofthe24-hourHRVweresigniﬁcantlyimprovedin
the treated group. All these indices are considered to reﬂect
the parasympathetic system and being protective from a
cardiovascular disease viewpoint [25]. Furthermore, another
signiﬁcant improvement was the decrease in the LF/HF
ratio assessed during 24 hours and during daytime in the
treatment group. Accordingly, Poirier et al. observed that
the improvement in HRV after weight loss occurred mainly
during the daytime period [7]. Our results show similar
improvement in the parasympathetic modulation and in the
sympathovagal balance, particularly during daytime. Studies
[10, 14, 26] reported that, following bariatric surgery which
induced important weight loss in severely obese subjects,
LV mass was signiﬁcantly reduced. In our study, weight loss
in the treatment group was accompanied with a signiﬁcant
decrease in the posterior wall thickness and in LV mass as
also reported by others [27–29].
To our knowledge, there are no data available in severely
obese subjects investigating the impact of weight loss on
the pseudonormal pattern of LV ﬁlling using the Valsalva
manoeuvre. We observed an improvement of LV diastolic
function in over half of the treated subjects compared to
only one patient who had an improved LV diastolic function
in the control group. Of note, the relations between HRV
and echocardiographic parameters revealed that rMSSD and
HF values correlate with E/A ratio. Interestingly, we also
found a signiﬁcant positive correlation between changes in
E/A ratio and changes in LF/HF ratio during 24-hour and6 Journal of Obesity
P = .026
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Control group Treatment group
Normal LV diastolic function
Spontaneous LV diastolic dysfunction
Pseudonormal LV diastolic dysfunction
Figure 1: Changes in left ventricular (LV) diastolic function in both groups pre and posttreatment.
daytime. These associations suggest that improvement in the
parasympathetic function is related to improvement in the
cardiac LV diastolic function parameters, as we previously
reported in overweight subjects with diabetes [21]. Of note,
there are only few reported studies using pharmacological
approach in severely obese patients [30–32] and HRV and
diastolic function has not been evaluated within the same
study in this population.
The magnitude of weight loss induced by the medication
is smaller (2.9 ± 2.5%) but may be comparable to ﬁndings
previously reported, accounting for the time-treatment
period. Sj¨ ostr¨ om et al. have reported a 10% weight lost
(10kg) after a year of treatment with Orlistat in a cohort
of overweight to severely obese subjects [33]. Other studies
using Orlistat foralongerperiod (12to24months) havealso
reported similar results [34–39]. Taking into account that
our study only lasted three months, we may speculate that
subjects of our study could have possibly lost comparable
amount of weight if had our study lasted 12 months.
Indubitably, the deﬁnitive treatment in this obesity category
is bariatric surgery, but clinicians aim at a 5%–10% weight
loss in order to achieve better metabolic proﬁle in obese
subjects [1, 15]. Fasting glycemia signiﬁcantly decreased
in the treated group in contrast to the control group.
Accordingly, Fujioka et al. [40]r e p o r t e dt h a te v e r y4 . 5 k g
reduction in weight should result in a 1.1mmol/L decrement
in fasting glycemia and to a 0.5% reduction in HbA1c.
Accordingly, HbA1c values have signiﬁcantly decreased in
the treated group. However, we also observed a signiﬁcant
decrease in HbA1c in the control group, which was not
diﬀerent to the decrease observed in the treated group. We
also observed a signiﬁcant decrease in LDL cholesterol in
the treated group as well as in the control group. This is
not unusual and it is often encountered in placebo groups
of weight loss studies. Indeed, similar results have been
reported in obese subjects after a 4-week run-in period
before treatment with Orlistat [34, 35]. Studies [38, 39]i n
overweight to obese type 2 diabetic patients with longer
treatment duration (6 to 12 months) resulting to greater
weight loss report greater changes in metabolic proﬁles,
leading after 12 months to signiﬁcant diﬀerences between
Orlistat-treated group and control group.
We acknowledge that this study includeda small number
of subjects. Therefore, it should be considered as a pilot
study. However, weight loss was signiﬁcant in the treated
group whereas it was not in the control group. Also, aJournal of Obesity 7
few echocardiographic measurements, mainly those regard-
ing the pulmonary veins assessment, were not adequately
recorded because of technical reasons due to the corpulence
ofthe subjects. Mitral inﬂow velocitiesare knownto be load-
dependent. Other indices of LV diastolic function, such as
tissue Doppler-derived indices, may be less load-dependent.
However, Dumesnil et al. [41] reported that tissue Doppler-
derived indices are not totally preload independent and
should be interpreted in light of the other Doppler param-
eters and the use of Valsalva’s manoeuvre.
5.Summary
The aim of this study was to determine the impact of
Orlistat-induced weight loss on the metabolic proﬁle and
cardiovascular function in severely obese type 2 diabetes
patients. Twenty-nine severely obese patients with type 2
diabetes were randomized either to a nonplacebo control
group or to a treatment group with Orlistat thrice a day.
Metabolic proﬁle, anthropometric parameters, heart rate
variability indices, and echocardiographic variables were
measured before and after a 12-week treatment period. Our
results suggest that a modest weight loss improves fasting
glycemia, diastolic function, and sympathovagal balance in
severely obese patients with type 2 diabetes.
6.Conclusions
Despite modest but signiﬁcant weight loss, we observed
that subjects treated with Orlistat showed improvements in
fasting glycemia. We also observed improvements in HRV as
well as in the LV diastolic function. The improvement in the
cardiac parasympathetic ANS modulation was associated
with enhancement in LV diastolic function. Our results
emphasize the beneﬁt of even modest weight loss in severely
obese patients with diabetes.
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